Hypertension strategies in the third millennium: conservatism, evidence and the folly of speculation
Explore this paper's citation graph
Summary
It is increasingly apparent, that the specific strategies used to modify (vascular risk factors) make a critical difference in patient outcomes and guidelines and performance measures should reflect the evidence about interventions that are known to be beneficial.
- Type
- letter
- Published
- 2009-01-01
- Cited by
- 4
- References
- 51
- Access
- Open access
- OpenAlex
- https://openalex.org/W2017811396
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:27107623
Keywords
Medicine, Intensive care medicine, Coronary artery disease, Observational study, Speculation
References
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
- β‐blockers as fourth‐line therapy for hypertension: stay the course
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
- Beta‐blockers should remain as first‐line therapy in the management of hypertension
- Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
- High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
- The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial
- Evidence that new antihypertensives are superior to older drugs.
- Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
- Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study.
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
- [Should beta-blockers remain first choice in the treatment of primary hypertension?].
- Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group.
- A likely explanation for the J-curve of blood pressure cardiovascular risk.
- Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
- Redefining quality--implications of recent clinical trials.
- Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
- The OPTIMAAL trial: losartan or captopril after acute myocardial infarction.
- Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?
Cited by
- Single‐pill combination therapy in hypertension: a rational or emotional construct?
- Pedeset godina tiazida i tiazidima sličnih diuretika
- The Study of Hardiness and Its Association with Aggression and Interpersonal Sensitivity in Physicians
- Changes of circulating ghrelin and obestatin levels in obese patients with or without type 2 diabetes mellitus
Related papers
- Science & Speculation
- Speculation in the Housing Market?
- Commodity and Food Speculation, Is There a Need for Regulation? A Discussion of the International Research
- SPEKULASI POSITIF VS SPEKULASI NEGATIF (Sebuah Penjelasan Tentang Hubungan Antara Risiko dan Spekulasi)
- Does Speculation Belong in Social Science Research?
- 8.5. Problems of morality in the financial sphere
- The Impact of Global Financial Crisis on Speculation in Housing Markets of China
- Speculation and Housing Prices